Gosset Ownership
Private
Employees
~200
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
GenVivo General Information
GenVivo’s lead candidate GEN2 has entered Phase 1 trials for cancer. It uses a proprietary HSV-eTK gene and GM-CSF to induce tumor cell death and stimulate immune response. Other programs are at preclinical or IND-enabling stages. Rexin-G was previously approved in the Philippines for solid tumors.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
San Marino, California
United States
United States
Drug Pipeline
GEN2
Phase 1Key Partnerships
Not specified in public sources.
GenVivo Funding
No funding data available
To view GenVivo's complete valuation and funding history, request access »